Cytek Biosciences (CTKB)
(Delayed Data from NSDQ)
$5.30 USD
-0.05 (-0.93%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $5.30 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Price, Consensus and EPS Surprise
CTKB 5.30 -0.05(-0.93%)
Will CTKB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CTKB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CTKB
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Lags Revenue Estimates
Cytek Biosciences (CTKB) Moves 5.1% Higher: Will This Strength Last?
CTKB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Tops Revenue Estimates
Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates
Cytek Biosciences, Inc. (CTKB) Stock Moves -0.33%: What You Should Know
Other News for CTKB
Cytek Biosciences (CTKB) Receives a Buy from Piper Sandler
Cytek Biosciences price target lowered by 50c at Piper Sandler, here's why
Cytek Biosciences: Hold Rating Amidst Mixed Performance and Cautious U.S. Market Outlook
Cytek Biosciences, Inc. (CTKB) Q2 2024 Earnings Call Transcript
Cytek Biosciences to Participate in Upcoming Investor Conferences